Plasma Copeptin Levels Are Inversely Associated with Intima-media-thickness in Men: the Population-based KORA F4 Study

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2013 Nov 13

PMID 24215469

Citations 2

Authors

Cornelia Then

Bernd Kowall

Andreas Lechner

Christa Meisinger

Margit Heier

Wolfgang Koenig

Annette Peters

Joachim Thiery

Wolfgang Rathmann

Jochen Seissler

Affiliations

Soon will be listed here.

Abstract

Background: Elevated plasma preprovasopressin (copeptin) levels are associated with cardiovascular complications as well as with an increased risk for type 2 diabetes (T2D). Here, we studied, whether plasma copeptin is related to carotid intima-media thickness (IMT), a measure of early atherosclerosis, and may thus be one explanation for the high cardiovascular risk in T2D.

Methods: Plasma concentrations of copeptin and IMT of the common carotid artery were determined in 1275 participants of the population-based KORA F4 study. We used linear regression models to investigate associations between copeptin levels and IMT.

Results: In the whole study group, copeptin levels were not significantly associated with IMT after adjustment for age and sex. Copeptin and IMT were significantly inversely associated after multivariable adjustment in the total cohort (β = -0.020 mm, 95% CI: -0.037 mm; -0.003 mm), in men (β = -0.035 mm, 95% CI: -0.061 mm; -0.009 mm) and in study participants with prediabetes (β = -0.041 mm, 95% CI: -0.078 mm; -0.005 mm) comparing quartile 4 vs quartile 1. The negative association of copeptin and IMT in men was present after adjustment for age alone. In women and patients with T2D, copeptin was not significantly associated with IMT.

Conclusions: Plasma copeptin was not associated with an increased IMT in our study cohort. In contrast, copeptin levels were related to a lower IMT in men and subjects with prediabetes, suggesting that elevated copeptin concentrations do not exert proatherogenic effects on carotid arteries.

Citing Articles

Association of C-Terminal Pro-Endothelin-1 with Mortality in the Population-Based KORA F4 Study.

Then C, Sujana C, Herder C, Then H, Heier M, Meisinger C Vasc Health Risk Manag. 2022; 18:335-346.

PMID: 35535305 PMC: 9078871. DOI: 10.2147/VHRM.S363814.

Association Between Circulating Copeptin Level and Mortality Risk in Patients with Intracerebral Hemorrhage: a Systemic Review and Meta-Analysis.

Zhang R, Liu J, Zhang Y, Liu Q, Li T, Cheng L Mol Neurobiol. 2016; 54(1):169-174.

PMID: 26732599 DOI: 10.1007/s12035-015-9626-z.

References

Saleem U, Khaleghi M, Morgenthaler N, Bergmann A, Struck J, Mosley Jr T . Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009; 94(7):2558-64. PMC: 2708945. DOI: 10.1210/jc.2008-2278. View

Bhandari S, Loke I, Davies J, Squire I, Struck J, Ng L . Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2008; 116(3):257-63. DOI: 10.1042/CS20080140. View

Ye Z, Ali Z, Klee G, Mosley Jr T, Kullo I . Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease. Am J Hypertens. 2013; 26(4):495-502. PMC: 3626040. DOI: 10.1093/ajh/hps073. View

Wang Y, Crofton J, Liu H, Sato K, Share L . V2-receptor blockade enhances pressor response to vasopressin: gender difference. Life Sci. 1996; 59(8):695-703. DOI: 10.1016/0024-3205(96)00351-7. View

Holmberg L, Nilsson I, Borge L, Gunnarsson M, Sjorin E . Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med. 1983; 309(14):816-21. DOI: 10.1056/NEJM198310063091402. View

Karakas M, Januzzi Jr J, Meyer J, Lee H, Schlett C, Truong Q . Copeptin does not add diagnostic information to high-sensitivity troponin T in low- to intermediate-risk patients with acute chest pain: results from the rule out myocardial infarction by computed tomography (ROMICAT) study. Clin Chem. 2011; 57(8):1137-45. DOI: 10.1373/clinchem.2010.160192. View

De Marchis G, Katan M, Weck A, Fluri F, Foerch C, Findling O . Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology. 2013; 80(14):1278-86. DOI: 10.1212/WNL.0b013e3182887944. View

Stachenfeld N, Splenser A, Calzone W, Taylor M, Keefe D . Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol (1985). 2001; 91(4):1893-901. DOI: 10.1152/jappl.2001.91.4.1893. View

Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M . Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond). 2012; 37(4):598-603. DOI: 10.1038/ijo.2012.88. View

10.

Garcia-Villalon A, Sanz E, Monge L, Fernandez N, Martinez M, Climent B . Vascular reactivity to vasopressin during diabetes: gender and regional differences. Eur J Pharmacol. 2003; 459(2-3):247-54. DOI: 10.1016/s0014-2999(02)02826-1. View

11.

Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda F . Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010; 55(19):2096-106. DOI: 10.1016/j.jacc.2010.01.029. View

12.

Seissler J, Feghelm N, Then C, Meisinger C, Herder C, Koenig W . Vasoregulatory peptides pro-endothelin-1 and pro-adrenomedullin are associated with metabolic syndrome in the population-based KORA F4 study. Eur J Endocrinol. 2012; 167(6):847-53. DOI: 10.1530/EJE-12-0472. View

13.

Li X, Yang X, Sun Q, Chen X, Li Y . Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease. Chin Med J (Engl). 2013; 126(5):823-7. View

14.

Kowall B, Ebert N, Then C, Thiery J, Koenig W, Meisinger C . Associations between blood glucose and carotid intima-media thickness disappear after adjustment for shared risk factors: the KORA F4 study. PLoS One. 2013; 7(12):e52590. PMC: 3528645. DOI: 10.1371/journal.pone.0052590. View

15.

Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort R, Gans R . Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012; 55(7):1963-70. DOI: 10.1007/s00125-012-2545-x. View

16.

Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler N, Melander O . Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab. 2011; 96(7):E1065-72. DOI: 10.1210/jc.2010-2981. View

17.

Meijer E, Bakker S, Halbesma N, de Jong P, Struck J, Gansevoort R . Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 2009; 77(1):29-36. DOI: 10.1038/ki.2009.397. View

18.

Stallone J . Role of endothelium in sexual dimorphism in vasopressin-induced contraction of rat aorta. Am J Physiol. 1993; 265(6 Pt 2):H2073-80. DOI: 10.1152/ajpheart.1993.265.6.H2073. View

19.

Maier C, Clodi M, Neuhold S, Resl M, Elhenicky M, Prager R . Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care. 2009; 32(10):1890-5. PMC: 2752942. DOI: 10.2337/dc08-2168. View

20.

Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler N . Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008; 52(4):266-72. DOI: 10.1016/j.jacc.2008.03.050. View